Companion Animal Osteoarthritis Market Report: Market Size & Forecast 2026

Companion animal osteoarthritis refers to chronic, progressive joint disease in pets, most commonly diagnosed in dogs but increasingly recognized in cats as well. The market encompasses pharmaceuticals, biologics, nutritional supplements, and medical devices used to manage pain and improve mobility. Global revenues were estimated near $2.895 billion in 2025, with growth driven by both higher case identification and broader treatment adoption.

• •Canine osteoarthritis is the largest animal segment, reflecting the high prevalence of hip and elbow dysplasia in dogs.
• •Treatment categories typically span NSAIDs, disease-modifying osteoarthritis drugs, monoclonal antibody therapies, and joint health supplements.
• •North America leads the market today, while Europe and Asia-Pacific represent the fastest-expanding regions.

Rising pet ownership and the trend toward treating pets as family members are pushing owners toward more advanced and ongoing veterinary care. Improved diagnostic imaging and greater veterinary awareness have increased the rate of osteoarthritis identification, particularly in cats where the condition was historically underdiagnosed. A maturing pipeline of biologic and regenerative therapies is also expanding the addressable market beyond traditional pain management.

• •Humanization of pets has lifted per-animal spending on chronic disease management.
• •New biologic and monoclonal antibody approvals have widened treatment options for moderate-to-severe cases.
• •Greater clinical recognition of feline osteoarthritis is opening a previously underserved patient population.

By product, the market is typically split across pharmaceuticals, biologics, and nutritional supplements, with pharmaceuticals historically dominant but biologics growing fastest. Canine applications account for the majority of revenue, while feline and other companion animals form a smaller but accelerating segment. Geographically, North America holds the largest share, followed by Europe, with Asia-Pacific and Latin America identified as the highest-growth regions.

• •Biologics are forecast to grow faster than traditional pharmaceuticals due to premium pricing and targeted mechanisms of action.
• •Distribution is split between veterinary hospital pharmacies, retail pharmacies, and online channels, with e-commerce expanding rapidly.
• •Emerging markets in Asia-Pacific are benefiting from rising disposable income and expanding veterinary infrastructure.

What are the recent trends and outlook?

The market outlook through the early 2030s is shaped by continued innovation in biologic therapies, expansion into feline osteoarthritis, and growing use of telemedicine and direct-to-consumer veterinary channels. Combination therapy approaches that pair pharmaceuticals with supplements, weight management, and physical rehabilitation are gaining traction as standards of care evolve. With a projected CAGR near 14.88%, the market is positioned to remain one of the faster-growing segments within veterinary therapeutics.

• •Long-acting injectable biologics are reducing reliance on daily oral medications and supporting treatment adherence.
• •Preventive care, including early screening and nutraceutical use in at-risk breeds, is becoming a strategic focus.
• •Digital health tools, including wearables that monitor mobility, are emerging as complementary diagnostic and monitoring solutions.